CA
NZ
UK
AU
IND
US
…
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -27.42M | -11.96M | -15.41M | -3.96M | -4.67M |
| Minority interest | - | - | - | - | 0.00M |
| Net income | -54.85M | -11.43M | -14.41M | -3.36M | -3.77M |
| Selling general administrative | 8.76M | 4.69M | 3.26M | 1.61M | 1.44M |
| Gross profit | -27.53M | -12.13M | -15.14M | - | 0.00M |
| Reconciled depreciation | 0.79M | 0.79M | 0.80M | 0.80M | 0.63M |
| Ebit | -27.53M | -12.13M | -15.14M | -3.94M | -4.51M |
| Ebitda | -12.20M | -10.76M | -5.63M | -3.12M | -3.88M |
| Depreciation and amortization | 15.32M | 1.37M | 9.51M | 0.82M | 0.63M |
| Non operating income net other | - | - | 0.00M | - | 0.00M |
| Operating income | -27.53M | -12.13M | -15.14M | -3.94M | -4.52M |
| Other operating expenses | 20.26M | 11.57M | 6.44M | 3.94M | 4.52M |
| Interest expense | 0.10M | 0.00M | 0.28M | 0.04M | 0.16M |
| Tax provision | 0.00M | -0.53M | -1.00M | -0.60M | -0.90M |
| Interest income | 0.10M | 0.01M | 0.00M | 0.01M | 0.02M |
| Net interest income | 0.10M | 0.01M | -0.28M | -0.03M | -0.14M |
| Extraordinary items | - | - | - | - | 0.00M |
| Non recurring | - | - | - | - | 0.00M |
| Other items | - | - | - | - | 0.00M |
| Income tax expense | 27.42M | -0.53M | -1.00M | -0.60M | -0.90M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 20.26M | 11.57M | 6.44M | 3.94M | 4.52M |
| Cost of revenue | 27.53M | 12.13M | 15.14M | - | 0.00M |
| Total other income expense net | 0.10M | 0.18M | -0.28M | -0.03M | -0.14M |
| Discontinued operations | - | - | - | - | 0.00M |
| Net income from continuing ops | -27.42M | -11.43M | -14.41M | -3.36M | -3.77M |
| Net income applicable to common shares | - | -11.43M | -19.04M | -3.86M | -3.77M |
| Preferred stock and other adjustments | - | - | - | - | 0.00M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 5.79M | 8.62M | 26.46M | 25.21M | 10.88M |
| Intangible assets | - | - | 8.06M | 8.85M | 9.64M |
| Other current assets | 0.93M | 1.88M | 1.76M | 0.55M | 0.32M |
| Total liab | 0.80M | 1.15M | 0.98M | 2.27M | 2.87M |
| Total stockholder equity | 4.99M | 7.47M | 25.49M | 22.94M | 8.01M |
| Deferred long term liab | - | - | - | 0.53M | - |
| Other current liab | 0.34M | 0.59M | 0.68M | 0.70M | 0.24M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -75.37M | -64.25M | -36.82M | -25.40M | -10.98M |
| Other liab | - | - | - | 0.93M | 1.53M |
| Other assets | 0.00M | - | 0.01M | 0.16M | 0.01M |
| Cash | 4.71M | 6.50M | 16.50M | 15.42M | 0.69M |
| Total current liabilities | 0.73M | 1.00M | 0.97M | 1.22M | 1.19M |
| Net debt | -4.56M | -6.27M | -16.42M | -15.09M | 0.34M |
| Short term debt | 0.08M | 0.08M | 0.07M | 0.20M | 0.88M |
| Short long term debt | - | - | - | 0.12M | 0.80M |
| Short long term debt total | 0.15M | 0.23M | 0.08M | 0.33M | 1.03M |
| Other stockholder equity | 80.36M | 71.72M | 62.31M | 48.33M | 18.99M |
| Property plant equipment | - | - | 0.07M | 0.16M | 0.23M |
| Total current assets | 5.63M | 8.39M | 18.33M | 16.20M | 1.01M |
| Net tangible assets | - | - | 17.43M | 14.09M | -1.63M |
| Net receivables | - | - | 0.07M | 0.23M | - |
| Long term debt | - | - | - | 0.04M | - |
| Accounts payable | 0.31M | 0.33M | 0.22M | 0.32M | 0.08M |
| Accumulated other comprehensive income | 0.00M | - | - | - | -0.02M |
| Common stock total equity | - | - | - | 0.00M | 0.00M |
| Retained earnings total equity | - | - | - | -25.40M | - |
| Non currrent assets other | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Non current assets total | 0.15M | 0.23M | 8.14M | 9.01M | 9.88M |
| Capital lease obligations | 0.15M | 0.23M | 0.08M | 0.17M | 0.23M |
| Long term debt total | - | - | - | 0.04M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | - | - | - | 0.00M | -0.02M |
| Change to liabilities | - | -0.10M | 0.25M | -0.22M | 0.24M |
| Total cashflows from investing activities | - | - | - | - | -0.02M |
| Net borrowings | - | - | 0.86M | 0.81M | 0.81M |
| Total cash from financing activities | -0.39M | 9.80M | 17.87M | 1.70M | 2.62M |
| Change to operating activities | - | -1.08M | -0.39M | 0.04M | -0.05M |
| Net income | -27.42M | -11.43M | -14.41M | -3.36M | -3.77M |
| Change in cash | -9.99M | 1.08M | 14.72M | -1.05M | -1.11M |
| Begin period cash flow | 16.50M | 15.42M | 0.69M | 1.74M | 2.85M |
| End period cash flow | 6.50M | 16.50M | 15.42M | 0.69M | 1.74M |
| Total cash from operating activities | -9.61M | -8.72M | -3.14M | -2.75M | -3.71M |
| Issuance of capital stock | 0.00M | 10.05M | 17.10M | 0.00M | 2.87M |
| Depreciation | 0.79M | 0.79M | 0.80M | 0.80M | 0.63M |
| Other cashflows from investing activities | - | - | - | - | 0.00M |
| Dividends paid | - | - | - | - | 0.00M |
| Change to inventory | - | - | - | - | 0.00M |
| Change to account receivables | - | 0.01M | -0.08M | -0.08M | -0.08M |
| Sale purchase of stock | -0.39M | -0.06M | 17.10M | - | 0.00M |
| Other cashflows from financing activities | -0.09M | -0.19M | 0.77M | 1.70M | -0.25M |
| Change to netincome | - | 3.10M | 10.41M | -0.02M | -0.83M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.02M |
| Change receivables | - | - | -0.16M | - | 0.00M |
| Cash flows other operating | - | - | 8.36M | - | 0.00M |
| Exchange rate changes | - | - | - | - | 0.00M |
| Cash and cash equivalents changes | - | - | 14.72M | - | 0.00M |
| Change in working capital | 0.54M | -1.18M | -0.14M | -0.18M | 0.19M |
| Stock based compensation | 8.83M | 3.41M | 2.73M | 0.51M | 0.07M |
| Other non cash items | 7.66M | 0.22M | 8.88M | 0.08M | 0.07M |
| Free cash flow | -9.61M | -8.72M | -3.14M | -2.75M | -3.73M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| PCSA Processa Pharmaceuticals Inc |
- -% |
1.89 | - | - | - | 0.96 | -0.02 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.
7380 Coca Cola Drive, Hanover, MD, United States, 21076
443 776 3133
13
| Name | Title | Year Born |
|---|---|---|
| Dr. David Young Ph.D., Pharm.D. | Co-Founder, Pres, CEO & Director | 1953 |
| Mr. Patrick Lin | Co-Founder, Chief Bus. & Strategy Officer | 1965 |
| Dr. Sian E. Bigora Ph.D., Pharm.D. | Co-Founder & Chief Devel. Officer | 1960 |
| Ms. Wendy J. Guy | Co-Founder, Chief Admin. Officer & Corp. Sec. | 1964 |
| Mr. James H. Stanker | Chief Financial Officer | 1958 |
| Mr. Robert Michael Floyd | Chief Operating Officer | 1956 |
| Mr. George K. Ng Esq., J.D. | Chief Executive Officer | 1974 |
| Dr. David Young Ph.D., Pharm.D. | Co-Founder, President of Research and Development & Director | 1953 |
| Dr. Sian E. Bigora Ph.D., Pharm.D. | Co-Founder and Chief Development & Regulatory Officer | 1960 |
| Mr. Patrick Lin | Co-Founder, Chief Business & Strategy Officer | 1965 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...